Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Search

Total 166 results found. Search for [ Bayer ]

Results 100 to 120 of 166
P.B. Jayakumar
March 5, 2015
The US is mounting pressure on India to agree to its terms in pharma IP protection. How long can India resist?


www.businesstoday.in
February 13, 2015
Gadgets and Gizmos tells you about the newest gadgets and technology in the market and what these offer.


E Kumar Sharma
January 17, 2015
The Indo-US talks in January, to be held just days before President Barack Obama visits India to attend the Republic Day celebrations, are part of a work plan on IPR agreed upon by both nations in November.


E Kumar Sharma
December 18, 2014
Experts say the Novartis-Cipla case raises similar issues that previous cases did - non-availability of drugs, non-working of patent in India and unaffordable pricing.


Tanvi Varma
November 21, 2014
The markets have been getting strong support from foreign institutional investors, or FIIs, who pumped in Rs 5,700 crore this week despite the rupee weakening by 2.5 per cent.


Abhishek Vishnoi
Mumbai, November 12, 2014
The stock was headed towards its biggest single-day gain since August 2014 after Bayer's profit for the September-quarter rose by 51 per cent to Rs 176 crore.


E Kumar Sharma
August 30, 2014
The technology provider, which has provisional turnover of Rs 25 crore, offers IT solutions to agribusiness companies and farmers alike.


Manoj Kumar
May 1, 2014
Commerce Secretary Rajeev Kher praised a decision by the US Trade Representative not to label India with its worst offender tag in an annual scorecard on protecting U.S. patents, copyrights and other intellectual property.


PTI
New Delhi, April 26, 2014
With this acquisition, EID Parry would ensure reliable sourcing of Astaxanthin for its subsidiary US Nutraceuticals LLC (Valensa). The entire production of Alimtec will be used by Valensa for its Astaxanthin products catering to US and Europe markets, the filing added.


Mail Today Bureau
New Delhi, March 24, 2014
Commerce and industry minister Anand Sharma on Sunday came out strongly to defend India's track record on intellectual property rights and said that the country is ready to take on the US at the World Trade Organization (WTO) over the issue.


Bill Berkrot
February 8, 2014
The US Chamber of Commerce has requested that India be classified as a Priority Foreign Country, a tag given to the worst offenders when it comes to protecting intellectual property and one that could trigger trade sanctions.


Sumeet Chatterjee and Ben Hirschler
Mumbai/London, February 6, 2014
Global pharmaceutical firms are pressuring the United States to act against India to stop more local companies producing up to a dozen new varieties of cheap generic drugs still on-patent.


E. Kumar Sharma
December 7, 2013
There are more than a dozen drugs in important cancer treatment areas that are not available in India. The new drug flow into India has slowed down significantly and it is a matter of concern for oncologists and cancer patients.


PTI
Mumbai, November 23, 2013
The exchange, Asia's oldest, will include Axis Bank in the S&P BSE Sensex and Aditya Birla Nuvo in the S&P BSE 100 index effective December 23.


PTI
New Delhi, August 28, 2013
In reply to allegations made by Novartis on India's 'discriminatory' patent practices, the government has said global firms have benefited more from the country's rules than suffer from them.


PTI
Mumbai, August 2, 2013
The Intellectual Property Appellate Board (IPAB) has revoked the patent granted to the British drug major GlaxoSmithKline Pharma for its breast cancer drug Tykerb.


PTI
New Delhi, April 20, 2013
German drug major Bayer AG on Friday said it \"disagrees\" with a US court ruling that allowed Indian rival Lupin to sell generic version of its oral contraceptive (OC) tablet 'Yaz' in the American market and is \"evaluating\" options.


E. Kumar Sharma
April 13, 2013
The Supreme Court decision on Glivec sets the tone for other patent disputes and puts global drugmakers on the back foot.


BT Online Bureau
New Delhi, April 1, 2013
The Intellectual Property Appellate Board had denied the patent right for the drug to Novartis in 2006. The Swiss pharma major had in 2009 taken its challenge against a law that bans patents on newer forms of known drugs to the Supreme Court.


E Kumar Sharma
March 28, 2013
Novartis and many companies see the final decision on Glivec, whose generic versions are currently sold in the Indian market, as a landmark judgment for it would bring clarity on the interpretation and implementation of the Indian Patents Act.


PAGES 6 OF 9  6789